Movement Alert|ILUVATAR COREX Rises 4.13% in Regular Trading, Multiple Institutions Maintain Bullish Ratings Supporting Post-Selloff Rebound

Market Focus
Yesterday

On September 9, ILUVATAR COREX rose 4.13% in regular trading, trading at 354.2 HKD/share, with turnover of 107 million HKD. The stock had plunged over 11% the prior week and has now posted consecutive sessions of technical rebound.

On the news front, multiple institutions reaffirmed bullish stances. Macquarie maintained its Outperform rating and target price of 1,060 HKD, citing the company's penetration into China's cloud service provider (CSP) clients and the expected ramp-up of its next-generation GPGPU chips. The broker noted that mass production of the Tiangai-300 training chip could begin as early as Q4, with meaningful revenue contribution anticipated next year. Guosheng Securities also maintained a Buy rating, projecting core GPU products to continue driving earnings growth.

Fundamentally, the company reported H1 revenue of 9.46 billion yuan, up 191.6% year-over-year, while adjusted net profit reached 2.46 billion yuan, marking a turnaround from losses. Inference GPU revenue surged 651.8%, becoming the primary growth engine at 69.2% of total revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10